A Randomised, Double-blind, Placebo-Controlled, Phase 2/3 Study with 2 Doses of Calmangafodipir in Increased Risk Patients Treated with N‑Acetylcysteine for Paracetamol Overdose

The aim of the POP2 trial is to determine the most effective dose of Calmangafodipir against a placebo for patients who present to the Emergency Deparmtnet with a hepatic injury.

Status: coming-soon

Coordinated by

Julia Grahamslaw and Caroline Blackstock

Main Trial Site

Royal Infirmary of Edinburgh